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1. Introduction    
Inflammatory bowel disease (IBD) comprises two main chronic pathologies of the 
gastrointestinal tract: ulcerative colitis (UC) and Crohn’s disease (CD), both characterized by 
alternating phases of active inflammation and clinical remission with different 
complications and extraintestinal manifestations (Colletti, 2004; Hanauer & Hommes, 2010). 
The ethiopathogenesis of IBD has still not been elucidated, but it has been suggested that 
inflammatory processes emerge in genetically susceptible individuals as a result of an 
irregular, over-expressed immunological reaction to some undefined food antigens or some 
other agents of microbial origin (Baumgart et al., 2011).  
Given the complexity of etiological factors in human IBD, a lot of current knowledge 
regarding IBD pathogenesis has arisen from the study of various animal models. 
Although no ideal model of IBD has been accomplished so far, they resemble different 
important clinical, histopathological and immunological aspects of human IBD 
(Mizoguchi & Mizoguchi, 2010). Chemically induced murine models by oral 
administration of dextran sulfate sodium (DSS) and intrarectal application of 2,4,6-
trinitrobenzene sulfonic acid (TNBS) are the most commonly used ones, due to their onset 
and duration of colonic inflammation which is immediate, reproducible and shares a lot 
of similarities with human IBD. TNBS-induced colitis is one of the most accepted and 
used Crohn-like disease while the DSS-model is clinically and histologically similar to 
human ulcerative colitis (Wirtz & Neurath, 2007). These models, together with other 
animal models of IBD, have given insight in different processes at the molecular level and 
have revealed the importance of different molecules involved in IBD etiology, 
representing therefore essential tools in investigating different mechanisms underlying 
acute or chronic inflammation in the IBD (Uhlig & Powrie, 2009). 
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Growing body of knowledge proposes proteases as key factors in the occurrence of 
inflammatory processes due to their ability to metabolize different biologically active 
molecules implicated in maintaining the integrity of mucosal barrier (Ravi et al., 2007). 
Dipeptidyl peptidase IV, known also as CD26 molecule (DPP IV/CD26) is one of them 
(Gorrell et al., 2001). DPP IV/CD26 is also T-cell differentiation antigen, expressed on 
various cell types, having numerous functions in a variety of biological processes, as well as 
immunological mechanisms (Fleischer, 1994). It is also present in a soluble form circulating 
in body fluids in living organisms with specific peptidase function having unique features 
in substrate processing: it cleaves dipeptides from the N terminus of polypeptides having 
proline or alanin at the penultimate position. Since Xaa-Pro peptides are not easily 
metabolized by other proteases, the action of DPP IV/CD26 is an essential step in the 
degradation of many polypeptides (Gorrell et al., 2001). Numerous biologically important 
cytokines, chemokines and neuropeptides with potential and/or confirmed role in IBD 
ethiopathogenesis are effective DPP IV/CD26 substrates (Mentlein, 2004).  
Previous studies proposed a role of DPP IV/CD26 in the pathogenesis of IBD, given its 
involvement in immune regulations via its expression on immune cells and capability to 
cleave biologically active molecules (Hildebrandt et al., 2001; Varljen et al., 2005). 
Additionally, DPP IV/CD26 inhibitors have been pointed out as therapeutic agents in 
ameliorating inflammatory processes in immunologically mediated diseases such as IBD 
(Yazbeck et al., 2009; Yazbeck et al., 2008). 
The aim of this study was to review our previously published results regarding correlation 
between disease severity and serum DPP IV/CD26 activity in young and adult patients 
affected with IBD. Furthermore, our aim was to investigate and review does it and in which 
manner DPP IV/CD26 affect the immune homeostasis during development, progression 
and resolution of inflammatory events in two animal models of IBD. 
2. Dipeptidyl peptidase IV/CD26 molecule 
The exoprotease dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5), also known as surface 
antigen CD26, is a transmembrane glycoprotein with molecular mass of 220-240 kDa, 
expressed constitutively on a variety of cell types (Lambeir et al., 2003). It is also present in a 
soluble form in serum, saliva, urine and other biological fluids. So far, the role of this 
molecule has been investigated in different fields of biochemistry, immunology, 
endocrinology, oncology, pharmacology, physiology and pathophysiology. 
Structural and molecular characteristics  
According to the current biochemical and structural data, DPP IV/CD26 is a type II 
transmembrane, homodimeric glycoprotein. Each monomer consists of a large extracellular 
part (739 amino acids), a hydrophobic transmembrane segment of 23 amino acids and a 
short cytoplasmic N-terminal tail. The primary sequence of DPP IV/CD26 is composed of 
766 amino acids and it was found to be conserved in different species (85% similarities 
between rat and human and 92% similarities between rat and mouse), mostly in the C-
terminal protease segment (Lambeir et al., 2003). DPP IV/CD26 is a member of the POP 
(prolyl oligopeptidase) gene family with an ǂ/ǃ hydrolase domain and a N-terminal ǃ-
propeller domain that enclose the large cavity (30-40 Å) which contains a small pocket with 
the active site. The catalytic site, as a part of extracellular domain of the molecule, contains 
Ser-630, His-740 and Asp-708, which is not common for classical serine-type peptidases, but 
is characteristic for the previously mentioned ǂ/ǃ hydrolase fold (Gorrell et al., 2006).  
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Based on structural and biochemical features, DPP IV/CD26 is a member of a family of DPP 
IV activity and/or structure homologue (DASH) proteins, which also includes quiescent cell 
proline dipeptidase (QPP), DPP8, DPP9, fibroblast activation protein (FAP), attractin and 
DPP IV-ǃ (Sedo & Malik, 2001). Since it is well known that most DASH proteins have 
protease activity, having the possibility to modify the activity of biologically active peptides, 
it could be suggested that they are important regulatory molecules (Gorrell, 2005). However, 
further research is necessary in order to clarify their biological role.   
Distribution and expression 
DPP IV/CD26 is widely distributed in mammalian tissues, mainly on epithelial and 
endothelial cell surfaces, as well as on fibroblasts and lymphocytes (Boonacker & Van 
Noorden, 2003). The expression of DPP IV/CD26 on hematopoietic cells is well regulated 
according to the activation status. In humans, it is expressed on a fraction of resting 
lymphocytes at low density, but is strongly up-regulated following T-cell activation (Fleischer, 
1987). In resting peripheral blood mononuclear cells, a small subpopulation of T cells expresses 
CD26 at high density on the surface (CD26-bright cells), which belongs to the CD45RO+ 
population of T cells (memory cells) (De Meester et al., 1999; Ishii et al., 2001). Moreover, CD26 
expression on T cells may correlate with T-helper subsets. High expression is found on Th1 
and Th0 cells, whereas Th2 cells display lower CD26 expression (Willheim et al., 1997).  
Soluble DPP IV/CD26 
Soluble DPP IV/CD26 activity was firstly discovered in the serum in 1968 by Nagatsu et al. 
(Nagatsu et al., 1968). Later, DPP IV/CD26 activity has been shown in other body fluids 
including plasma, serum, cerebrospinal and synovial fluids, semen and urine. Although 
soluble DPP IV/CD26 lacks the transmembrane domain and intracellular tail, due to 
glycosylations processes, its molecular weight is similar to the transmembrane form. The 
origin of the soluble DPP IV/CD26 is still not elucidated, but it was suggested that it could 
be released from the surface of all CD26 expressing cells in contact with blood by proteolytic 
cleavage (Gorrell et al., 2001). The physiological role of soluble DPP IV/CD26 in biological 
fluids with respect to the transmembrane DPP IV/CD26 remains poorly understood, but 
according to previous findings it has been proposed that, as an enzyme, it is involved in the 
regulation of many processes in human body (Aytac & Dang, 2004; Mentlein, 1999).  
Functions in immune regulations 
Immune regulation is a complex and important process in which DPP IV/CD26 as a 
costimulatory molecule in T-cell activation and a regulator of the functional effect of selected 
biological factors through its enzyme activity, certainly has an important function 
(Boonacker & Van Noorden, 2003).  Furthermore, biochemical and immune studies provide 
evidence that CD26 interacts with many biologically important molecules including CD45, 
adenosine deaminase protein, chemokine receptor CXCR4 on the surface of human 
peripheral blood lymphocytes (Herrera et al., 2001) and the mannose-6-phosphate/insulin-
like growth factor II receptor (Ikushima et al., 2000). The costimulatory properties of DPP 
IV/CD26 have been studied extensively, although different experimental settings 
sometimes provide conflicting results. It is generally  accepted that several distinct anti-
CD26 mAbs have costimulatory activities in anti-CD3-driven activation of pure T-cell 
subsets (either CD4+ or CD8+ T cells), and that the extent and kinetics of the response differs 
between mAbs, recognizing different epitopes. High CD26 surface expression is correlated 
with the production of Th1-type cytokines such as IFN-Ǆ (Reinhold et al., 1997b). 
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Furthermore, CD26+ CD4+ T cells support differentiation of B cells into antibody-producing 
plasma cells (Dang et al., 1990). 
The question whether the DPP IV/CD26 enzyme activity is involved in T cell activation is 
still controversial (Lambeir et al., 2003; Schon et al., 1985). Upon CD26-mediated 
costimulation, IL-2 production is higher in cells expressing wild-type CD26, suggesting that 
the DPP IV enzymatic activity of CD26 might contribute to, but is not essential for signal 
transduction. On the other hand, studies with inhibitors of DPP IV/CD26 activity have 
demonstrated that DPP IV/CD26 plays a key role in T cell activation (Munoz et al., 1992). It 
was shown that antigen-specific T cell proliferation and IL-2 production in vitro could be 
inhibited by application of the chemical inhibitor Pro-boro-Pro (Flentke et al., 1991). In 
addition, Lys(Z(NO2))-thiazolidide, Lys(Z(NO2))-piperidide, and Lys(Z(NO2))-pyrrolidide, 
all synthetic competitive DPP IV/CD26 inhibitors, significantly inhibit DNA synthesis and 
the production of IL-2, IL-10, IL-12 and IFN-Ǆ in pokeweed mitogen-stimulated purified T 
lymphocytes (Hildebrandt et al., 2000; Thompson et al., 2007). On the other hand, the 
presence of these inhibitors enhance the secretion of the immune-inhibitory cytokine TGF-
ǃ1, suggesting that TGF-ǃ1 helps regulate DPP IV/CD26 effect on T cell function (Reinhold 
et al., 1997a). 
DPP IV/CD26 substrates 
 
Neuropeptides Glucose regulators 
Neuropeptide Y Glucagon 
Vasoactive intestinal peptide Glucagon-like peptide 1 (GLP-1) 
Peptide YY Glucagon-like peptide 2 (GLP-2) 
Endomorfin 1 and 2 Gastrin-releasing peptide 
Beta-casomorphine  
Substance P  
Mediators of inflammation Other bioactive peptides 
Stromal cell derived factor- 1α and 1β      
(SDF-1α and 1β) 
Bradykinin  
Growth hormone-releasing factor 
RANTES 
(regulated on activation, normal T-cell 
expressed and secreted) 
Prolactin  
Enterostatin 
Alpha-1-microglobulin 
Interleukines: IL-1, IL-2, IL-6, IL-10 Monomeric fibrin (α chain) 
Tumor necrosis factor α (TNF-α) Melanostatin 
Macrophage-derived chemokine Tripsinogen 
Interferon-inducible protein 10 (IP-10)  
Eotaxin  
Table 1. Selected DPP IV/CD26 biologically important substrates (Gorrel et al, 2006) 
Firstly, DPP IV/CD26 was considered to cut off distinctively after a proline or an alanine on 
the second position from the N-terminal end of a polypeptide chain. Meanwhile, the list of 
DPP IV/CD26 substrates has been enlarged as it has been shown that a DPP IV/CD26 
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substrate could also have a serine, glycine, valine, threonine, leucine, or hydroxyproline at 
the penultimate position (Lambeir et al., 2001). However, DPP IV/CD26 is unable to 
hydrolyze substrates with proline, hydroxyproline or N-methyl glycine on the third position 
from the N-terminus (Puschel et al., 1982) and therefore, these peptides are DPP IV 
inhibitors.  
A large number of various biologically important peptides have been shown to be substrates 
of DPP IV/CD26. Some of the most important DPP IV/CD26 substrates are presented in 
Table 1.  
3. Inflammatory bowel disease and DPP IV/CD26 
During the past 50 years, IBD affected millions of people worldwide and therefore has 
become one of the major gastroenterological problems, especially in the Westernized world. 
It is a disorder of multiple etiologies, with generally accepted definition that occurs in 
genetically susceptible individuals, under influence of environmental and microbiological 
factors, as an overexpressed immunological response to antigens of unknown origin, 
characterized by chronic uncontrolled inflammation of intestinal mucosa, resulting in its 
destruction and lost of its function (Colletti, 2004). IBD comprises two main chronic 
inflammatory diseases of humans, namely ulcerative colitis and Crohn's disease, both 
characterized by alternating phases of active inflammation and clinical remission with 
diverse complications and extraintestinal manifestations (Hanauer & Hommes, 2010). 
Although the scientific knowledge increases exponentially, there are still many 
unanswered questions in several fundamental aspects of the IBD. The most stimulating 
field of IBD research is the interaction among the three major factors of the 
pathophysiology, including genetic predisposition, environmental bacteria and immune 
deregulation. The early inductive phases of these diseases are particularly difficult to 
study in humans because patients usually come to clinic only after their symptoms have 
been established (Hanauer, 2006). 
3.1 Clinical relevance of serum DPP IV/CD26 activity in adult patients and children 
with IBD 
Many investigations and reviews have discussed the role of DPP IV/CD26 activity in 
inflammation and the potential usefulness of this protein in therapeutics and diagnostics 
purpose (Hildebrandt et al., 2001; Varljen et al., 2005). However, its exact role still remains 
unclear. In clinical practice, the differential diagnosis of CD and UC is often difficult. 
Different biochemical, clinical, endoscopic, pathological and histological features should be 
combined in order to allocate the appropriate diagnosis. However, a precise diagnosis is not 
possible in about 10% of patients with chronic colitis, which results in the designation 
»indeterminate colitis« (Geboes et al., 2008).  
Given the role of DPP IV/CD26 in the modulation of the immune response, we hypothesized 
that DPP IV/CD26 is altered in patients with CD and UC and that changes in DPP IV/CD26 
serum activity could be related to the disease activity together with other inflammatory 
parameters. Therefore, the aim of this study was to evaluate the clinical relevance of changes 
in serum DPP IV activity in adult patients IBD (CD and UC). Furthermore, given the different 
immune background in patients with CD and UC as well as different expression of DPP 
IV/CD26 on Th1 and Th2 cells, we wanted to evaluate if DPP IV/CD26 serum activity could 
be used as differentiating marker in the diagnosis of these diseases. 
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3.2 Material and methods 
Adult patients 
The study was performed on 62 patients, 38 with CD (mean age ± SD: 42.7±14.4; 19 males, 19 
females), and 24 with UC (mean age ± SD: 45.6±17.6; 13 males, 11 females). All patients were 
admitted to the Department of Gastroenterology, Clinical Hospital Centre Rijeka. Diagnoses 
of CD or UC were established on the basis of clinical history, laboratory, endoscopic and 
histological data. The control group included 65 healthy donors (mean age ± SD: 41.6±12.1; 
32 males, 33 females). The CD activity was evaluated using the Crohn’s Disease Activity 
Index (CDAI), while the UC activity was evaluated according to the Truelove and Witts’ 
(TW) classification (Truelove & Witts, 1955). The localization of the disease was determined 
according to the Wienna classification for CD while UC was divided into proctosigmoiditis, 
left-side colitis and pancolitis. Blood samples were obtained after all patients and controls 
signed informed consents under the protocols approved by the Ethics Committee.  
Children 
The study involved also young patients, 31 children with IBD. Diagnoses of CD or UC were 
established on the basis of clinical history, laboratory, endoscopic and histological data. CD 
activity was evaluated by using the Paediatric Crohn´s Disease Activity Index (PCDAI) 
(Hyams et al., 1991). Blood samples were obtained after all children’s parents gave their 
signed informed consent under the protocols approved by the Ethics Committee. The study 
group comprised 24 patients with CD (12 with (PCDAI)≥15 and 12 with (PCDAI)<15) and 7 
with UC. Their mean ± SD age at diagnosis was 13.84±1.72 years. The control group 
included 46 healthy children (mean age ± SD: 13.80±2.83 years; 22 males and 24 females).  
3.2.1 DPP IV/CD26 assay 
Sera were separated from fasting blood samples and stored at –80°C until thawed for enzyme 
activities. Determination of serum DPP IV/CD26 activities was performed as described by 
Kreisel et al (Kreisel et al., 1982). DPP IV/CD26 activities were determined by measuring the 
release of 4-nitroaniline from an assay mixture containing 0.1 mol Tris-HCl (pH 8.0), 2 mmol 
Gly-Pro p-nitroanilide (Sigma Chemical, Steinheim, Germany) as the substrate and serum in a 
total volume of 0.20 mL. After 30 minutes of incubation at 37°C, the reaction was stopped by 
the addition of 800 μL of 1 mol sodium acetate buffer (pH 4.5). The absorbance at 405 nm was 
measured by use of a Varian Cary UV/VIS spectrophotometer (Cary, NC). All of the reactions 
were performed in duplicate. Enzyme activities in serum were expressed as μmol of 
hydrolyzed substrate in a volume of 1 dm3 per minute under the assay conditions.  
3.3 Results and discussion 
Here reviewed results for adult patients were previously published in Croatica chemica acta, 
(Varljen et al., 2005), while results of investigations that included children were previously 
published in Pediatric Gastroenterology - Reports from the 2nd World Congress of Pediatric 
Gastroenterology, Hepatology and Nutrition (Varljen et al., 2004). 
Adult patients 
Results of serum DPP IV/CD26 activity in adult patients with CD and UC compared to the 
control group are presented on Fig. 1. It could be seen that both serum DPP IV/CD26 activities 
in CD as well as UC are statistically significantly (P < 0.05) reduced compared to healthy controls. 
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Fig. 1. Serum DPP IV/CD26 activity in patients affected with Crohn’s disease (CD) and 
ulcerative colitis (UC) compared to healthy controls. 
When analyzing the correlation between serum DPP IV/CD26 activity in patients with CD 
and UC, it was noticed that patients affected with CD, having CDAI>250 had statistically 
significantly lower serum DPP IV/CD26 activity compared to patients having CDAI<150 (Fig. 2). 
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Fig. 2. Serum DPP IV/CD26 activity in three groups of patients with Crohn’s disease. 
Likewise, an inverse correlation between serum DPP IV/CD26 activity and disease severity 
was found in patients affected with UC (Fig. 3). It could be seen that patients with severe UC 
had statistically significantly (P < 0.05) lower DPP IV/CD26 activity compared to patients 
having mild UC. 
Children 
In young patients affected with IBD, DPP IV/CD26 activity in serum was also reduced 
compared to the levels in healthy controls, likewise in adult patients. The serum DPP 
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Fig. 3. Serum DPP IV/CD26 activity in two groups of patients with ulcerative colitis. 
IV/CD26 activity in children with CD was statistically significantly (P < 0.05) decreased 
compared to the levels in healthy controls. The DPP IV/CD26 activity in children with UC 
was also decreased but not statistically significantly when compared to controls (Fig. 4). 
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Fig. 4. Serum DPP IV/CD26 activity in children affected with Crohn’s disease (CD) and 
ulcerative colitis (UC) 
The serum DPP IV/CD26 activity in children with active CD was statistically significantly 
decreased (P < 0.05) compared with the levels in healthy controls, while in patients with 
inactive CD it was also found to be decreased, but not statistically significantly (Fig. 5). 
Based on obtained results, it could be concluded that soluble DPP IV/CD26 in serum seems 
to be involved in the pathophysiology of IBD and appears to be useful as an available non-
invasive marker in the diagnosis of disease activity. Changes of DPP IV/CD26 expression 
and serum activity were found to occur in several clinical and experimental situations of 
altered immune function (Gorrell et al, 2006). Results of our study accord with previous 
investigation which confirmed lower serm DPP IV/CD26 activity in patients affected with 
IBD (Hildebrandt et al., 2001; Rose et al., 2003). Obtained data, together with previously 
published results, suggest that the persisted immune dysbalance could have a significant 
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impact on the pathogenesis of IBD. Our results can suggest a functional 
compartmentalization of DPP IV/CD26, which can be interpreted as an adaptive systemic 
immune response to a local inflammatory reaction. Meanwhile, the obtained results do not 
corroborate the hypothesis that the serum DPP IV/CD26 enzymatic activity differs between 
patients with CD and patients with UC, thus reflecting the concept of different cytokine 
patterns in one or the other subtype of IBD. Consequently, it seems that the serum DPP 
IV/CD26 activity could not be used as a specific differential diagnostic marker between CD 
and UC, and further investigations are necessary in order to establish a new parameter for 
differentiation of CD from UC. 
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Fig. 5. Serum DPP IV/CD26 activity in children affected Crohn’s disease (CD),  
4. Animal models of IBD 
Throughout the last decade, several experimental animal models of IBD have been 
developed in order to define different components of the pathophysiological processes that 
characterize these disorders (Mizoguchi & Mizoguchi, 2010; Strober et al., 1998; Wirtz & 
Neurath, 2007). Experimental animal models have a number of advantages which include 
allowing the study of specific pathophysiological events occurring before symptoms onset. 
Furthermore, investigators can perform genetic and immunologic manipulations of relevant 
mouse genes, possibly involved in disease pathogenesis (Bhan et al., 1999). 
Although no ideal model of IBD has been accomplished so far, they resemble different 
important clinical, histopathological and immunological aspects of human IBD. The value of 
the animal models is the insight they allow into the complex, multifaceted processes and 
mechanisms that can result in acute or chronic intestinal inflammation. Animal models of 
IBD have given insight in different processes at the molecular level and have revealed the 
importance of different molecules involved in IBD etiology, representing therefore essential 
tools in investigating different mechanisms underlying acute or chronic inflammation in 
IBD.  In recent years quite a number of new experimental models of intestinal inflammation 
have been described (Table 2).  
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Animal model Disease type 
Spontaneous  
C3H-HeJBir Colitis, superficial, acute-resolving, Th1 
SAMP1/Yit Ileitis, chronic, transmural, granulomatous, Th1 
SAMP1/YitFc Perianal disease, early onset of disease 
  
Genetically engineered   
IL-2 knockout Spontaneous colitis, Th1 
IL-10 knockout 
Colitis, acute, chronic, transmural, Th1 (early)/Th2 
(late) 
T-cell receptor ǂ mutant mice Colitis, chronic, Th2 
TNF-3’ UTR knockout mice Colitis 
STAT-4 transgenic mice Colitis, acute, chronic, transmural, Th1 
IL-7 transgenic mice Colitis, acute, chronic, Th1 
HLA B27 transgenic Spontaneous, entire colon, Th1 
  
Chemically induced  
Trinitrobenzene sulfonic acid-induced colitis Colitis, acute, chronic, transmural, Th1 
Oxazolone colitis Colitis, Th2 
Dextran sulfate sodium colitis Colitis, superficial, Th1 (acute), Th1/Th2 (chronic) 
Peptidoglycan-polysaccharide colitis Enterocolitis, transmural 
  
Adoptive transfer   
CD4/CD45RBhigh T-cell transfer colitis Colitis, chronic transmural, Th1 
Transfer of hsp60-specific CD8 T cells Colitis, Th1 
TNF, Tumor necrosis factor; UTR, untranslated region; STAT, signal transducer and activating 
transcription; hsp, heat shock protein 
Table 2. Selected animal models of IBD (Mizoguchi & Mizoguchi, 2010) 
4.1 DSS-induced colitis (ulcerative-like model of colitis) 
Ulcerative colitis (UC) is a chronic inflammatory condition of the colon that may affect 
individuals of any age. It generally begins in the anus and extends at a variable length 
from the rectum in a continuous fashion. Patients usually present with a constellation of 
symptoms including diarrhea, lower abdominal cramping and tenesmus (Shah & Feller, 
2009). The dextran sulfate sodium (DSS) model of induced colitis is an excellent 
preclinical animal model that exhibits numerous phenotypic features with human 
ulcerative colitis. It was originally described by Ohkusa et al. (Ohkusa, 1985) as a hamster 
model and was adapted to mice subsequently by Okayasu and its coworkers (Okayasu et 
al., 1990).  
DSS is a polyanionic derivate of dextrane produced by esterification with chlorosulphonic 
acid. The exact mechanism through which DSS initiates colitis is unknown but according to 
previously published data, it is supposed that DSS alternates the gut permeability. It was 
shown that administration of DSS reduces the expression of tight junction proteins like zona 
occludens-1, leading to increased gut permeability. Another suggested mechanism involves 
direct cytotoxic action of DSS on the colonic mucosa, which leads to the alteration of 
integrin-ǂ4 and M290 subunit levels on epithelial cells. Through these effects, DSS induces 
mucosal injury with consequent activation of immune response, leading to the development 
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of acute or chronic colitis (Dieleman et al., 1998). Inflammation induced by DSS is most 
frequent and severe in the distal part of the colon (Okayasu et al., 1990) and its severity 
depends on the concentration and molecular weight of DSS (Kitajima et al., 2000). 
Concentrations described in literature range between 1% and 7%, while the most commonly 
used molecular weight ranges between 30 kDa and 50 kDa.  
4.1.1 Induction of DSS-colitis in mice 
This study was performed using pathogen-free, male, 8-10-week-old (weighting 20±2 g) 
wild type (C57BL/6) mice and mice with inactivated gene for DPP IV/CD26 molecule 
(CD26-/-) generated on a C57BL/6 genetic background, as described previously (Marguet et 
al., 2000). CD26-/- mice were kindly provided by Dr. Didier Marguet, Centre d’Immunologie 
Marseille-Luminy, France. Animals were housed and bred under standard conditions at the 
Central Animal Facility of the School of Medicine, University of Rijeka. 
Colitis was induced in both mice strains using 3% (w/v) sodium dextran sulfate sodium 
(DSS; MW 50 kDa; MP Biomedicals, USA) during seven days in drinking water ad libitum 
(Wirtz & Neurath, 2007). Control mice received regular drinking water throughout the 
experiment (days 1-15).  
Handling with animals, experimental procedures and anesthesia were performed in 
accordance with the general principles contained in the Guide for the Care and Use of 
Laboratory Animals (National Academic Press). The Ethical Committee at the School of 
Medicine, University of Rijeka approved all of the experiments.   
Experimental design  
Animals included in the study were randomly divided into four groups as follows: C57BL/6 
and CD26-/- mice treated with the 3% DSS solution for 7 days and control C57BL/6 and 
CD26-/- group treated with tap water. At day 7, in order to compare the colitis severity, 
treated and control animal of each genotype were anesthetized by intraperitoneal 
administration of ketamine (2.5 mg/mice) and sacrificed by cervical dislocation. The 
remaining animals were given normal drinking water until day 15 when they were 
sacrificed in order to compare the strain difference during colitis resolution. At each time 
point, 6-8 animals of each group were sacrificed. During the entire experiment, body mass 
was measured daily and clinical symptoms were assessed using the disease activity score. 
The colon segments from the ileocecal valve to the anus were excised post mortem, washed 
with ice-cold phosphate-buffered saline (PBS) and their length and weight were measured, 
as indirect markers of inflammation. After colon length and weight measurements, tissue 
samples were opened longitudinally, washed in PBS and proceeded for histology, 
morphometry and biochemical analysis. Morphometrical measurements included evaluation of  
crypt number, crypt depth and crypt width on hematoxilin - eosin stained tissue samples. 
Analyses were performed using software Issa (VAMS, Zagreb, Croatia), Pulmix camera 
(TMC 76S, Japan) and Olympus BX 40 microscope. 
The clinical score was assessed as described previously (Howarth et al. 2000; Murthy et al. 
1993). Briefly, weight loss of >5% was scored as 0 points, weight loss of 5 to 10% as 1 point, 
10 to 15% as 2 points, 15 to 20% as 3 points, and more than 20% as 4 points. For stool 
consistency, 0 points were given for well formed pellets, 2 points for pasty and semiformed 
stools that did not stick to the anus, and 4 points for liquid stools that remained adhesive to 
the anus. Bleeding was scored 0 points for no presence of rectal bleeding and 4 points for 
gross bleeding from the rectum. These scores were added and divided by three, resulting in 
a total clinical score ranging from 0 (healthy) to 4 (maximal activity of colitis). 
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Mucosa fractions isolation from duodenum, jejunum, ileum and colon segments were 
prepared from mucosal scrapings according to Ahnen et al. (Ahnen et al., 1982).  
4.1.2 Establishment and validation of the DSS-induced colitis at systemic  
and local level 
Oral administration of DSS in rodents induces a colonic inflammation with many 
similarities to human IBD. Consistent with previous studies, as disease progressed, clinical 
symptoms, including loss of body mass, changes of stool consistency and appearance of 
rectal bleeding, were aggravated. Until day 3, no clinical symptoms of colitis were seen. 
From day 3 and later, both mice strain showed blood in their feces and diarrhea. From the 
results presented in Table 3, it could be concluded that body mass of healthy animals, 
control group, CD26-/- mice, in comparison to the control C57BL/6 mice is lower which is in 
agreement with previously published data (Marguet et al., 2000). Administration of the DSS 
solution caused a statistically significant decrease (P < 0.05) of body mass on day 3 in 
C57BL/6 mice, while in CD26-/- mice, extensive body mass loss began one day after, with a 
maximum fall on the ninth day. As the inflammation progressed, the disease activity index 
(DAI) in each group, increased gradually and reached its maximum on day 7 in both mice 
strains. Body weight increased gradually in both control groups. Variations in clinical 
symptoms and body mass during colitis development, established in C57BL/6 and CD26-/- 
mice, are shown in Table 3. 
 
Mice 
strain 
Day of 
experiment 
Body  
mass (g) 
DAIa Diarrheab 
Gross 
bleedingb 
Colon 
length 
(cm)a 
C57BL/6 
0 24.17 ± 1.97 0 0/6 0/6 8.5 ± 0.1 
7 19.19 ± 3.62 4.00 ± 0.20 6/6 6/6 7.3 ± 0.4 
15 23.35 ± 2.79 0 0/6 0/6 8.0 ± 0.2 
CD26-/- 
0 23.63 ± 1.73 0 0/6 0/6 8.5 ± 0.1 
7 19.35 ± 2.16 3.66 ± 0.25 6/6 5/6 7.7 ± 0.2 
15 21.57 ± 1.55 0.33 ± 0.05 0/6 0/6 8.0 ± 0.3 
aData are presented as mean ± SD 
bNumber of mice with diarrhea or gross bleeding/total number of mice in each group 
DSS: dextran sulfat sodium; DAI: Disease activity index 
Table 3. Changes of clinical variables during DSS-induced colitis development and 
resolution in C57BL/6 and CD26-/- mice. 
In order to assess the degree of inflammation at the local level, length and weight of each 
colon sample was measured. Statistically significant shortening of the colon was observed 
on day 7 of the experiment in both CD26-/- and C57BL/6 mice. Together with colon 
shortening, statistically significant increase of colon weight was observed on day 7 and 15 in 
CD26-/- and C57BL/6 mice. It is known that during colitis development, DSS induces colon 
tissue obliteration, but recent studies in rats showed that changes through the small 
intestine are also present (Geier et al., 2009; Ohtsuka & Sanderson, 2003). Therefore, in order 
to provide further evidence, we isolated small intestinal and colonic mucosa and measured 
the changes of mucosa weight during colitis development. A significant decrease of colonic 
mucosa weight was observed in C57BL/6 mice, while in CD26-/- mice the statistically 
significant decrease of ileum and colon mucosa weight was observed (Fig. 6). Our results 
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and results of previously published studies showed that DSS-induced damage could extend 
to the small intestine and therefore, further studies are necessary to validate physiological 
impact of this damage.  
                     
  
A 
 
 
B 
Data are presented as mean ± SD 
*P < 0.05, statistically significantly different compared to day 0 
Fig. 6. Influence of DSS-induce damage on small intestine and colon mucosa weight during 
colitis development and resolution in C57BL/6 (A) and CD26-/- (B) animals. 
In compliance with our results, it could be concluded that administration of DSS in drinking 
water for seven days resulted in a prominent colon inflammation and gastrointestinal 
dysfunction, followed by regeneration of the colonic epithelium in C57BL/6 and CD26-/- 
mouse strains. Shortening of the colon and increase of colon weight, as macroscopic 
measures for the degree of inflammation, correlates with changes of mucosa weight and 
pathological changes (Okayasu et al., 1990). Given the fact that the symptoms of 
inflammation were the most prominent between the seventh and tenth day following DSS 
administration, this period was classified as acute phase, which is in accordance with 
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previously reported findings. Furthermore, our findings suggest and confirm that the DSS 
model of colitis, because of similarities to human IBD, represents a good model to study the 
molecular and immune mechanisms activated during colitis development and resolution.  
In accordance with previously published histological data regarding colonic inflammation 
present in DSS model of colitis, inflammatory changes are superficial, mainly affecting the 
mucosa, but may extend to the submucosa and the muscularis mucosa as well. The 
inflammation is characterized by superficial ulcers, mucosal oedema, crypt distortion and 
mucosal inflammatory cell infiltration with large numbers of neutrophils, macrophages and 
lymphocytes (Cooper et al., 1993). Pathohistological and morphometrical analyses of colon tissue 
sections confirmed the presence of inflammatory changes in both mice strains. During colitis 
development, a statistically significant decrease in number of crypts of Lieberkühn per 
milimetar of mucosa followed by its shortening was recorded in both mice strains along 
with the infiltration of inflammatory cells in lamina propria (Fig. 7). In the acute phase ( day 
7), crypt architectural distortion reached its maximum and during this phase, typical sign of 
disease, patches of totally destroyed epithelial sheet with deep ulcerations, can be seen. The 
resolution of inflammation and regeneration of crypts started during the second week and 
finished on the day 15 (Fig. 7D). In this period, mononuclear types of inflammatory cells 
were predominant. 
 
                       
                                    
 
 
 
 
 
 
 
 
                                     
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Histological changes in colon tissues during dextran sulfate sodium-induced (DSS) 
colitis development and resolution in CD26-/- animals. Normal colon (A), acute phase of 
colitis (B) and process of tissue damage resolution (C, D). Colon sections (2 μm) were 
stained with hematoxylin and eosin and examined for histological properties.  
Magnification: 20x (A, C, D); 10x (B).  
A B
C D 
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There is evidence that susceptibility to DSS varies with the animal species and mice strain. 
Guinea pig is the most susceptible, with inflammation usually fully established in less than 
72 h (Iwanaga et al., 1994). In mice, some strains such as C3H/HeJ and C3H/HeJ Bir were 
found to be highly susceptible, while others such as NON/LtJ were quite resistant to DSS 
colitis (Mahler et al., 1998). Our results are in agreement with previously published study 
regarding the intensity of clinical symptoms between C57BL/6 and CD26-/- mice. Given the 
fact that there is no statistically significant difference in the intensity of clinical symptoms 
between mice strains it could be suggested that CD26 deficiency does not increase resistance 
to the development of DSS-induced experimental colitis (Geier et al., 2005).  
4.1.3 DPP IV/CD26 and DPP IV/CD26-like activity in DSS-colitis 
Functional studies have demonstrated that inhibition of DPP IV/CD26 enzyme activity may 
lead to changes in chemokine regulation and a subsequent immunological effect, while in 
vitro studies using activated T lymphocytes have shown that inhibition of DPP IV/CD26 
activity can result in a decreased secretion of proinflammatory cytokines, including TNF-ǂ 
and IFN-Ǆ as well as an increase in the anti-inflammatory cytokine TGF-ǃ. This evidence 
suggests that DPP IV/CD26 enzyme activity plays an essential role in the immune response 
and therefore, its enzymatic role is being extensively investigated. In our study, a 
statistically significant decrease in serum DPP IV/CD26 activity was observed in the acute 
phase in serum of C57BL/6 mice. The results regarding serum DPP IV/CD26 activity 
established in a DSS mouse model of colitis are consistent with our previous work in 
patients with IBD (Varljen et al., 2005). Furthermore, a decrease in DSS colitis disease 
activity was observed in wild type mice treated with inhibitors but on the other hand the 
inhibitors were not effective in CD26-/- animals (Yazbeck et al., 2010). Concurrently, during 
colitis development, an increased expression of DPP8 in wild type and CD26-/- animals and 
DPP2 mRNA expression in wild type animals was observed.   
Considering that DPP IV/CD26 is a member of a large S9b family of structurally 
homologous serine proteases that possess a unique catalytic activity, and since two recent 
studies have demonstrated a broad tissue distribution of DPP IV-like enzyme activity in 
both wild type and CD26-/-, a possible explanation of results obtained in our study could be 
that other DPP IV-like protease are involved in the activation of the inflammatory response 
in animal model of colitis (Ansorge et al., 2009; Yu et al., 2009). Furthermore, it was recently 
demonstrated by Yazbeck and its coworkers (Yazbeck et al., 2008) that inhibition of DPP-like 
activity ameliorates the severity of inflammation in experimental colitis in mice. However, 
further studies are required to characterize the role of DPP IV-like proteins in the initiation 
and activation of immune mechanisms leading to intestinal inflammation and development 
of IBD.  
4.2 TNBS-induced colitis (Crohn-like model of colitis) 
One of the most widely used and accepted Crohn-like colitis in scientific research is the 
TNBS-induced colitis. The TNBS-colitis resembles human Crohn’s disease in different 
aspects, from the clinical manifestation, histological appearance and immunological 
features. TNBS-colitis is induced in experimental animals by rectal application of TNBS in 
an adequate, experimentally determined dilution of ethanol, usually 30 to 50%. Ethanol 
serves as a barrier-breaker which allows TNBS molecules, a contact-sensitizing agent, to 
enter in deeper layers of the colonic mucosa. The mechanism of TNBS-induced 
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inflammation involves reaction of TNBS, which is a hapten, with tissue host proteins. TNBS 
is a covalently reactive compound that attachs to autologous proteins and stimulates a 
delayed-type hypersensitivity response (Camoglio et al., 2000). This generates a variety of 
new antigens in situ, as well as stimulates the production of proinflammatory molecules and 
free radicals which initiate a whole cascade of complex immunological interactions 
(Grisham et al., 1991). The colonic administration of a single dose of TNBS/ethanol solution 
induces in mice and rats a granulomatous, transmural inflammation with tissue destruction, 
mainly localized in the distal part of the colon (Scheiffele & Fuss, 2002). 
4.2.1 Induction of TNBS-colitis in mice  
Two mice strains were used in our study: wild type mice strain C57BL/6 and mice with 
inactivated gene for molecule CD26 (C57BL/6 Jbom-ob, CD26-/-), generated on a C57BL/6 
genetic background. CD26-/- mice were kindly provided by Dr. Didier Marguet, Centre 
d’Immunologie Marseille-Luminy, France. Generation of CD26-/- mice has been described 
previously (Marguet et al., 2000). Male, 8-10-week-old mice were used in the study. Animals 
were housed and bred under standard conditions at the Central Animal Facility of the 
School of Medicine, University of Rijeka. Laboratory animals were housed in plastic cages, 
fed with standard pellet food (MK, Complete Diet for Laboratory Rats and Mice, Slovenia), 
given tap water ad libitum and maintained under a 12/12 hours dark/light cycle at constant 
temperature (20±1)°C and humidity (50±5)%. Each study group comprised 8-10 
experimental animals. Handling with animals, experimental procedure and anesthesia were 
performed in accordance with the general principles contained in the Guide for the Care and 
Use of Laboratory Animals (National Academic Press). The Ethical Committee of the School 
of Medicine, University of Rijeka, approved all experimental procedures. 
TNBS-colitis was induced by rectal administration of 5% (w/v) TNBS (Sigma-Aldrich, 
Germany) dissolved in 50% ethanol (Kemika, Croatia). Each animal received 0.1 mL of 
TNBS-ethanol solution, using a vinyl catheter that was positioned 4 cm from the anus, 
according to the protocol of (Scheiffele & Fuss, 2002). Two control groups of mice were used 
for each mice strain. Control mice underwent identical procedures, but were instilled equal 
volumes of saline (NaCl 0.9%) or ethanol solution. Mice were anesthetized with 
ketamine/xylazine while receiving TNBS, saline or ethanol solution.  
4.2.2 Analytical methods 
Experimental animals were sacrificed by cervical dislocation after 2, 7, 15 and 30 days upon 
administration of TNBS, saline or ethanol solution. Peripheral blood samples were taken 
and serum samples were collected by centrifugation at 3000 rpm for 10 minutes. Livers and 
spleens were isolated and their weights were noted. Colons were freed from adhering tissue 
and macroscopic changes were noted. The colon lumen was carefully washed with ice-cold 
saline, its weight and length was measured after which underwent homogenization 
procedure. Brains were separated immediately after sacrifice, washed in ice-cold saline and 
then homogenized on ice. Colon and brain homogenates were centrifuged at 14000 rpm for 
20 minutes at +4°C. Resulting supernatants were measured for total protein concentrations 
according to the method of Bradford (Bradford, 1976).  
Colon tissues for histological and histomorphometrical analyses were collected and fixed in 4% 
formalin for 24 h. Samples were processed and embedded in paraffin wax. Two-micrometer 
sections were stained with hematoxylin and eosin. An experienced pathologist blinded to 
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treatment allocation scored microscopical changes, which included overall severity of 
mucosal damage, number of crypts of Lieberkühn and their depth and width.  
The DPP IV/CD26 (in C57BL/6) and DPP IV/CD26-like enzymatic activities (in CD26-/-  
mice) in mice serum, brain and colon homogenates were measured according to the protocol 
of (Kreisel et al., 1982), as described in section 3.2.1. 
Brain and colon samples for Western blot analyses of CD26 molecule expression were 
homogenized on ice using RIPA lysis buffer including inhibitors of proteases and 
phosphatases. After that, homogenates were centrifuged at 14000 rpm for 20 minutes at 
+4°C and resulting supernatants were measured for total protein concentrations according 
to the method of Bradford (Bradford, 1976). Equal amounts of total proteins were separated 
by SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis). Proteins were 
transferred from the gels to polyvinylidenedifluoride membranes by semi-dry 
electroblotting. Membranes were incubated overnight with primary anti-CD26 (Santa Cruz 
Biotechnology Inc., CA), followed by 45 min incubation with secondary antibody, 
horseradish peroxidase-conjugated mouse-anti-rabbit IgG (Santa Cruz Biotechnology Inc., 
CA). Membranes were incubated with chemiluminescent Amersham ECL-plus Western 
blotting detection reagents (Amersham, Little Chalfont, UK) and bands revealing protein 
expression of the CD26 molecule were visualized after exposure to photosensitive films 
(AGFA Ortho CP-G plus). Equal total protein loading was ensured with use of the primary 
mouse ß-actin antibody (Chemicon International, USA), and secondary horseradish 
peroxidase-conjugated goat-anti-mouse IgG (Santa Cruz Biotechnology Inc., CA). 
4.2.3 Evaluation of TNBS-colitis assessment 
All groups of experimental mice were monitored daily for their body weights, stool 
consistence and presence of blood, eventual occurrence of rectal bleeding and general 
clinical state. Characteristic findings associated with intrarectal administration of TNBS 
solution in mice included their poor clinical state, body weight loss up to 15% and a 
mortality rate of approximately 11% in both CD26-/- and C57BL/6 mice. Disease symptoms 
were mostly pronounced in the first five days of experiment.  
Body mass of individual experimental animals of all groups of both investigated mice 
strains were determined each day at about the same time, starting from the day of 
application of TNBS-ethanol solution, ethanol solution or saline, until the day of sacrifice 
(the second, seventh, fifteenth and thirtieth day). It has been noticed that body weights of 
CD26-/- animals, as compared to C57BL/6 strain of animals of the same age and gender, are 
statistically significantly different (P < 0.05) and amount (25.29±2.23)g for C57BL/6 and 
(23.41±2.51)g for CD26-/- animals. Lower body mass of CD26-/- animals in comparison with 
their genetic background (C57BL/6) mice as well as enhanced insulin secretion and 
improved glucose tolerance in mice lacking CD26 was reported before (Marguet et al., 2000).  
The weights of the brain, liver and spleen were measured analytically for each experimental 
animal and presented in Table 4.  
It was noticed that weights of livers and spleens were slightly higher in CD26-/- animals as 
compared to the corresponding groups of C57BL/6 animals, nevertheless their lower body 
mass. The trend of reduction in weight of liver and spleen on the second day of induction of 
colitis was observed in both strains of experimental animals. The hepatosomatic index 
(relative ratio of liver weight and body mass) and the relative ratio of spleen weight and 
body mass of animals were calculated for all animals. It was found that CD26-/- mice have 
statistically significantly higher (P < 0.05) values of the hepatosomatic index compared to  
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Mice 
strain 
Experimental 
group 
Day of 
experiment 
Brain mass (g) Liver mass (g) Spleen mass (g) 
C57BL/6 physiological 0 
0.44776 ± 
0.02273 
1.32092 ± 
0.11335 
0.07822 ± 
0.00951 
 colitis 2 
0.44733 ± 
0.02117 
0.89232 ± 
0.14574 
0.07596 ± 
0.01806 
 colitis 7 
0.44019 ± 
0.01498 
1.12842 ± 
0.19671 
0.08650 ± 
0.02623 
 colitis 15 
0.44037 ± 
0.03687 
1.24861 ± 
0.12537 
0.08424 ± 
0.02037 
 colitis 30 
0.44113 ± 
0.02342 
1.36642 ± 
0.14692 
0.07707 ± 
0.01311 
C57BL/6 physiological 0 
0.44776 ± 
0.02273 
1.32092 ± 
0.11335 
0.07822 ± 
0.00951 
 control 2 
0.44716 ± 
0.01527 
1.27890 ± 
0.15756 
0.07680 ± 
0.01630 
 control 7 
0.44488 ± 
0.00435 
1.23160 ± 
0.05487 
0.07462 ± 
0.00938 
 control 15 
0.44838 ± 
0.25067 
1.26048 ± 
0.05868 
0.07630 ± 
0.01327 
 control 30 
0.43701 ± 
0.03043 
1.35711 ± 
0.17414 
0.07728 ± 
0.00697 
CD26-/- physiological 0 
0.41532 ± 
0.02409 
1.43343 ± 
0.12470 
0.08170 ± 
0.01447 
 colitis 2 
0.41836 ± 
0.02203 
1.08765 ± 
0.12792 
0.06012 ± 
0.01982 
 colitis 7 
0.42448 ± 
0.02631 
1.53770 ± 
0.07895 
0.11080 ± 
0.04752 
 colitis 15 
0.42556 ± 
0.01740 
1.47498 ± 
0.18033 
0.11300 ± 
0.01758 
 colitis 30 
0.41040 ± 
0.01315 
1.36693 ± 
0.10567 
0.09158 ± 
0.02720 
CD26-/- physiological 0 
0.41532 ± 
0.02409 
1.43343 ± 
0.12470 
0.08170 ± 
0.01447 
 control 2 0.40117 ± 
0.02964 
1.33858 ± 
0.22979 
0.08222 ± 
0.03727 
 control 7 
0.41232 ± 
0.02331 
1.38604 ± 
0.07852 
0.08058 ± 
0.00259 
 control 15 
0.41924 ± 
0.03450 
1.24388 ± 
0.08975 
0.08260 ± 
0.00995 
 control 30 
0.42334 ± 
0.02402 
1.34925 ± 
0.24189 
0.08338 ± 
0.01257 
Table 4. Average brain, liver and spleen weights (g) for different groups of experimental 
animals at scheduled days of experiment. 
C57BL/6 animals. Hepatosomatic index decreased the second day of colitis induction in 
both strains of experimental animals, as a result of reduction in liver weight, despite of body 
weight loss. On the other hand, analyzed mice strains did not differ statistically significantly 
in the relative values of the ratio of spleen weight and body weight in physiological 
conditions, as well as in the control group treated with ethanol solution. Regardless of the 
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reduction of the weight of the spleen on the second day of induction of colitis in both strains 
of experimental animals, due to a reduction in body weights no statistically significant 
reduction in their relative ratios was observed. Statistically significant increase in the 
relative ratio of spleen weight and body mass was recorded in the group of CD26-/- animals 
on the fifteenth day of the induction of colitis, compared to the corresponding control group 
and compared to C57BL/6 animals sacrificed on the same day. 
Macroscopic examination of the distal part of the colon discovered localized inflammation 
with several ulcerations, mucosal erosions and bowel obstruction with enhanced edematous 
changes. Colon shortening and thickening with marked colonic edema, accompanied by 
increased colon weight and presence of hemorrhagic changes was most prominent two days 
following TNBS administration (Fig. 8). Therefore, day 2 of experiment was classified as 
acute phase of colitis, which is in accordance with previously reported findings (Scheiffele & 
Fuss, 2002).  
 
 
Fig. 8. Macroscopic appearance of the distal part of mice colons in the acute phase of colitis, 
two days after administration of TNBS-ethanol solution. 
Results of our histopathological analyses of colon tissue sections in wild type and CD26-/- 
mice that received TNBS-ethanol solution confirmed the presence of inflammatory processes 
and accomplishment of colitis induction. Microscopic changes, as well as macroscopic, were 
most conspicuous in the acute phase of colitis. Pathohistological analyses confirmed the 
presence of inflammatory changes very similar to those seen in human Crohn’s disease and 
revealed that under physiological conditions no differences in histological architecture was 
observed between analyzed mice strains (Fig. 9). 
Pathohistological analyses of a wider number of colonic section samples discovered some 
differences in the manifestation of inflammatory processes between CD26-/- and wild type 
mice: in CD26-/- mice, ulcerations were mainly localized in one part of the mucosal surface, 
and inflammatory changes did not overtake the entire mucosa. In most analyzed colon 
samples from CD26-/- mice, a part of the colonic mucosa was preserved with physiological 
appearance of crypts, but a transmural inflammation was observed in a number of mice 
(Fig. 10A). On the other hand, no transmural inflammatory changes were observed in wild 
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type animals, but in a number of experimental animals, inflammatory processes affected the 
entire colonic circumference with very little or no areas of preserved mucosa (Fig. 10B).  
 
 
A                        B 
Fig. 9. Histological appearance of colonic tissue sections of CD26-/- (A) and wild type mice 
(B) two days after application of saline solution. Colon sections (2 μm) were stained with 
hematoxylin and eosin and examined for histological properties. Magnification: 10x. 
 
                CD26-/-                  C57BL/6 
 
 
              A        B 
 
 
 
 
 
 
 
 
             C                       D 
 
 
 
 
 
 
 
 
Fig. 10. Pathohistological appearance of colonic tissue sections of CD26-/- (A, C) and wild 
type mice (B, D) in the acute phase of colitis, two days after application of TNBS-ethanol 
solution. Colon sections (2 μm) were stained with hematoxylin and eosin and examined for 
histological properties. Magnification: 4x (A, B), 10x (D) and 20x (C). 
Results of histomorphometrical analyses also confirmed the presence of inflammatory changes 
in both mice strains that received TNBS-ethanol solution. Number of crypts of Lieberkühn 
per mm of mucosa, and their depth and width for different groups of both mice strains at 
given days of experiment were measured (data not shown). Statistical analyses of obtained 
results among both control groups of animals did not reveal statistically significant changes 
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in observed parameters, nor at different days of sacrifice. In both mice strains with induced 
colitis, a statistically significant (P < 0.05) decrease in number of crypts of Lieberkühn per 
mm of mucosa was observed in the acute phase of colitis. Changes persisted even during 
tissue healing in CD26-/- mice. The width of crypts of Lieberkühn was increased in the acute 
phase of colitis in both mice strains, but it took longer to achieve physiological values in 
wild type mice. Furthermore, the depth of crypts of Lieberkühn was decreased in acute 
colitis in both mice strains. All those changes represent consequences of inflammatory 
processes in the colon which include mucosa thickening and formation of edema due to 
TNBS-ethanol-induced tissue damage. 
4.2.4 DPP IV/CD26 and DPP IV/CD26-like activity in TNBS-colitis 
Measurements of DPP IV/CD26 activity and protein expression in wild type mice were 
performed at systemic and local levels, in the serum and within the gut-brain axis 
respectively. Furthermore, in order to evaluate whether in conditions of DPP IV/CD26 
deficiency other DPP IV/CD26-like enzymes could partially undertake its enzymatic 
function, DPP IV/CD26-like systemic and local activities were determined in CD26-/- mice. 
Results of investigations concerning DPP IV/CD26 and DPP IV/CD26-like molecules in 
TNBS-induced colitis in mice reviewed here are accepted for publication in Croatica Chemica 
Acta (in press, vol.no.4, 2011). Fig. 11 shows results of serum DPP IV/CD26 activity in wild 
type mice with induced colitis compared to control groups. 
 
 
a, statistically significantly different compared to control group (P < 0.05) 
0 – control group, physiological condition; 2, 7, 15, 30 – days after administration of TNBS-ethanol 
solution (colitis group) or ethanol solution (control group). 
Fig. 11. Serum DPP IV/CD26 activity in C57BL/6 mice during colitis development and 
resolution compared to control group.  
A statistically significant decrease (P < 0.05) in serum DPP IV/CD26 activity, starting in the 
acute phase of colitis and achieving physiological values after disease healing could be seen. 
Our results accord with previously published results that included determination of serum 
DPP IV/CD26 activity in patients with IBD, as described before in this chapter. 
Furthermore, our results are in accordance with the observation that serum DPP IV/CD26 
activity correlates inversely with disease severity in patients with IBD (Varljen et al., 2005), 
since the lowest DPP IV/CD26 activity in mice was found in the acute phase of disease.  
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Furthermore, we wanted to evaluate possible changes in serum DPP IV/CD26-like activities 
during colitis development and healing as well. Therefore, CD26-/- mice with induced colitis 
as well as their control groups were analyzed. Obtained results showed that CD26-/- mice 
express approximately 10% of total serum DPP IV/CD26 activity detected in wild type mice. 
Fig. 12 shows results of serum DPP IV/CD26-like activity in CD26-/- mice with induced 
colitis compared to their control groups. 
 
 
0 – control group, physiological condition; 2, 7, 15, 30 – days after administration of TNBS-ethanol 
solution (colitis group) or ethanol solution (control group). 
Fig. 12. Serum DPP IV/CD26-like activity in CD26-/- mice during colitis development and 
resolution compared to control group.  
Our results indicated that there are no statistically significant differences in serum DPP 
IV/CD26-like activity between groups of CD26-/- animals with colitis and their control 
groups. Therefore, the significance of DPP IV/CD26 over DPP IV/CD26-like serum activity 
is proposed.  
4.2.5 DPP IV/CD26, IBD and the gut-brain axis 
Growing scientific evidence emphasizes neuroimmunomodulation as an important factor in 
the occurrence of inflammatory and autoimmune processes, as described in different 
investigations in the last few years (Ohman and Simren, 2010). The complex causal 
connection between central and enteric nervous system caused the introduction of the term 
gut-brain axis (Romijn et al., 2008). DPP IV/CD26 has previously been shown to play a key 
role in the metabolism of important bioactive neuro- and immunopeptides, as well as in the 
activation of the immune response (Vanderheyden et al., 2009). Due to its localization on the 
cell surface of the nervous and digestive system, likewise on the surface of important 
immune cells (Matteucci & Giampietro, 2009), we aimed to investigate possible changes in 
DPP IV/CD26 activity and protein expression at sight of inflammation, in the colon, and in 
which way those changes reflect on examined parameters in the brain.  
Results of our research showed an accentuated decrease in DPP IV/CD26 activity at site of 
inflammation, in the inflamed colon in wild type animals compared to their control groups 
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(Fig. 13A). On the other hand, an increased CD26 protein expression in the acute phase of 
disease was revealed by Western blotting technique (Fig. 13B). 
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Fig. 13. DPP IV/CD26 activity (A) and  protein expression (B) in colon of C57BL/6 mice 
during colitis development and resolution.  
Besides a regulatory system at the enzymatic level, this observed fact could also be partly 
explained as a compensatory mechanism, considering that a part of the decreased DPP 
IV/CD26 activity in the colon of wild type mice is indeed a consequence of severe mucosal 
damage induced by TNBS-ethanol solution. Consequently, increased CD26 protein 
expression in the acute phase of disease could represent an effort to realize a compensatory 
mechanism. Since damaged DPP IV/CD26 conformation is present in inflamed tissue, with 
the consequence of an improper enzyme activity, enhanced DPP IV/CD26 protein 
expression could represent a mechanism of feed-back. Our results are in agreement with 
previously reported observations regarding enhanced CD26 mRNA production in inflamed 
tissue (Nemoto et al., 1999).  
We have determined that, in physiological conditions, CD26-/- mice express less than 2% of 
total DPP IV/CD26 activity detected in the colon of wild type mice. This enzyme activity 
was defined as DPP IV/CD26-like activity in the colon and was investigated during colitis 
development and resolution, as well. Our results showed statistically significantly (P < 0.05) 
decreased DPP IV/CD26-like activity in inflamed colon homogenates in CD26-/- mice, 
compared to their controls (Fig. 14).  
www.intechopen.com
 Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
82
Nevertheless, this observation could not entirely be explained as a consequence of an 
intrinsic regulatory mechanism which downregulates the activity of DPP IV/CD26-like 
enzymes in inflammatory processes, but could also partially be attributable to tissue damage 
induced by TNBS/ethanol solution.  
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0 – control group, physiological condition; 2, 7, 15, 30 – days after administration of TNBS-ethanol 
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Fig. 14. DPP IV/CD26-like activity in colon of CD26-/- mice during colitis development and 
resolution compared to control group.  
DPP IV/CD26 and DPP IV/CD26-like activities were also analyzed in brain homogenates 
during colitis development and resolution in wild type and CD26-/- mice. Our results 
showed that DPP IV/CD26 activity in brain is statistically significantly decreased (P < 0.05) 
in the acute phase of colitis compared to control groups (Fig. 15A). On the other hand, CD26 
protein expression, as confirmed by Western blotting (Fig. 15B) remains constant. 
Furthermore, the activity of DPP IV/CD26-like enzymes was found to remain unchanged 
(Fig. 15C).  
It could be seen that changes in DPP IV/CD26 activity in the colon during inflammatory 
events, reflect on its activity in the central nervous system, which accentuates the 
importance of the gut-brain axis in IBD pathogenesis. Therefore, a decreased DPP IV/CD26 
activity in the brain is most probably causally connected with its accentuated changes in the 
colon. Furthermore, a regulatory mechanism which regulates DPP IV/CD26 activity in 
brain, independently of its protein expression is proposed.  
This study reveals new data about DPP IV/CD26 activity and protein expression in a model 
of Crohn-like colitis in mice. Likewise, due to very little available results of colitis 
investigation under conditions of CD26 deficiency, our study gives new insights in 
inflammatory manifestations induced by TNBS-ethanol administration in CD26 -/- mice.   
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a, statistically significantly different compared to control group (P < 0.05).  
0 – control group, physiological condition; 2, 7, 15, 30 – days after administration of TNBS-ethanol 
solution (colitis group) or ethanol solution (control group). 
Fig. 15. Brain DPP IV/CD26 activity and protein expression in C57BL/6 mice (A, B), DPP 
IV/CD26-like activity in CD26-/- mice (C) during colitis development and resolution.  
5. Conclusions 
Results of our studies show that DPP IV/CD26 is involved in the pathogenesis of IBD. In 
patients, its activity seems to be a good marker of disease activity, given its inverse correlation 
with disease severity. Given the potential role of DPP IV/CD26 in IBD, animal models of UC 
and CD have been established in CD26-/- and wild type mice. Our results showed that CD26-/- 
mice are not protected from two chemically induced colitis (DSS and TNBS colitis), but show 
specificity in histological damage compared to wild type mice, as well as differences in the 
www.intechopen.com
 Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
84
time course of the disease. When analyzing targeted immunobiochemical parameters, it was 
noticed that changes occurring during inflammatory processes in the colon reflect on 
investigated parameters in the central nervous system. Therefore, our results indicate and 
confirm the importance of the gut-brain axis in the pathogenesis of IBD.  
6. Acknowledgements 
This study was supported by the Croatian Ministry of Science, Education and Sports (grant 
No. 062-0061245-0213). We gratefully acknowledge Dr. Didier Marguet (Centre 
d’Immunologie Marseille-Luminy, France), for providing us CD26-/- mice. Many thanks to 
professor Siniša Volarević, PhD, head of the department of Molecular Medicine and 
Biotechnology and professor Stipan Jonjić, PhD, head of the department of Histology and 
Embryology, School of Medicine, University of Rijeka, for allowing us to complete a part of 
experiments using the equipment at their departments.  
7. References 
Ahnen, D.J.; Santiago, N.A.; Cezard, J.P. & Gray G.M. (1982). Intestinal 
aminooligopeptidase. In vivo synthesis on intracellular membranes of rat jejunum. 
J Biol Chem 257:12129-35. ISSN: 0021-9258 
Ansorge, S.; Bank, U.; Heimburg, A.; Helmuth, M.; Koch, G.; Tadje, J.; Lendeckel, U.; Wolke, 
C.; Neubert, K.; Faust, J.; Fuchs, P.; Reinhold, D.; Thielitz, A. & Tager, M. (2009). 
Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and 
aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 47:253-
61. ISSN: 1434-6621 
Aytac, U. & Dang, N.H. (2004). CD26/dipeptidyl peptidase IV: a regulator of immune 
function and a potential molecular target for therapy. Curr Drug Targets Immune 
Endocr Metabol Disord 4:11-8. ISSN: 1568-0088 
Baumgart, D.C.; Bernstein, C.N.; Abbas, Z.; Colombel, J.F.; Day, A.S.; D'Haens, G.; Dotan, I.; 
Goh, K.L.; Hibi, T.; Kozarek, R.A.; Quigley, E.M.; Reinisch, W.; Sands, B.E.; Sollano, 
J.D.; Steinhart, A.H.; Steinwurz, F.; Vatn, M.H. & Yamamoto-Furusho, J.K. (2011). 
IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: 
Proceedings of the World Digestive Health Day 2010 - Inflammatory bowel disease 
task force meeting. Inflamm Bowel Dis. Feb;17(2):639-44. ISSN: 1536-4844 
Bhan, A.K.; Mizoguchi, E.; Smith, R.N. & Mizoguchi, A. (1999). Colitis in transgenic and 
knockout animals as models of human inflammatory bowel disease. Immunol Rev 
169:195-207. ISSN: 0105-2896 
Boonacker, E. & Van Noorden, C.J. (2003). The multifunctional or moonlighting protein 
CD26/DPPIV. Eur J Cell Biol 82:53-73. ISSN: 0171-9335 
Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
72:248-54. ISSN: 0003-2697 
Camoglio, L.; te Velde, A.A.; de Boer, A.; ten Kate, F.J.; Kopf, M. & van Deventer, S.J. (2000). 
Hapten-induced colitis associated with maintained Th1 and inflammatory 
responses in IFN-gamma receptor-deficient mice. Eur J Immunol 30:1486-95. ISSN: 
0014-2980 
Colletti, T. (2004). IBD--recognition, diagnosis, therapeutics. Jaapa 17:16-8, 21-4. ISSN 1547-1896 
www.intechopen.com
 Role of Dipeptidyl Peptidase IV/CD26 in Inflammatory Bowel Disease 
 
85 
Cooper, H.S.; Murthy, S.N.; Shah, R.S. & Sedergran, D.J. (1993). Clinicopathologic study of 
dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-49. ISSN: 0023-
6837 
Dang, N.H.; Torimoto, Y.; Sugita, K.; Daley, J.F.; Schow, P.; Prado, C., Schlossman, S.F. & 
Morimoto, C. (1990). Cell surface modulation of CD26 by anti-1F7 monoclonal 
antibody. Analysis of surface expression and human T cell activation. J Immunol 
145:3963-71. ISSN: 0022-1767 
De Meester, I.; Korom, S.; Van Damme, J. & Scharpe, S. (1999). CD26, let it cut or cut it 
down. Immunol Today 20:367-75. ISSN: 0167-5699 
Dieleman, L.A.; Palmen, M.J.; Akol, H.; Bloemena, E.; Pena, A.S.; Meuwissen, S.G. & Van Rees, 
E.P. (1998). Chronic experimental colitis induced by dextran sulphate sodium (DSS) is 
characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385-91. ISSN: 0009-9104 
Fleischer, B. (1987). A novel pathway of human T cell activation via a 103 kD T cell 
activation antigen. J Immunol 138:1346-50. ISSN: 0022-1767 
Fleischer, B. (1994). CD26: a surface protease involved in T-cell activation. Immunol Today 
15:180-4. ISSN: 0167-5699 
Flentke, G.R.; Munoz, E.; Huber, B.T.; Plaut, A.G.; Kettner, C.A. & Bachovchin, W.W. (1991). 
Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and 
use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl 
Acad Sci U S A 88:1556-9. ISSN: 0027-8424 
Geboes, K.; Colombel, J.F.; Greenstein, A.; Jewell, D.P.; Sandborn, W.J.; Vatn, M.H.; Warren, 
B. & Riddell, R.H. (2008). Indeterminate colitis: a review of the concept--what's in a 
name? Inflamm Bowel Dis 14:850-7. ISSN: 1536-4844 
Geier, M.S.; Smith, C.L.; Butler, R.N. & Howarth, G.S. (2009). Small-intestinal manifestations 
of dextran sulfate sodium consumption in rats and assessment of the effects of 
Lactobacillus fermentum BR11. Dig Dis Sci 54:1222-8. ISSN: 1573-2568 
Geier, M.S.; Tenikoff, D.; Yazbeck, R.; McCaughan, G.W.; Abbott, C.A. & Howarth, G.S. 
(2005). Development and resolution of experimental colitis in mice with targeted 
deletion of dipeptidyl peptidase IV. J Cell Physiol 204:687-92. ISSN: 0021-9541 
Gorrell, M.D. (2005). Dipeptidyl peptidase IV and related enzymes in cell biology and liver 
disorders. Clin Sci (Lond) 108:277-92. ISSN: 0143-5221 
Gorrell, M.D.; Gysbers, V. & McCaughan, G.W. (2001). CD26: a multifunctional integral 
membrane and secreted protein of activated lymphocytes. Scand J Immunol 54:249-
64. ISSN: 0300-9475 
Gorrell, M.D.; Wang, X.M.; Park, J.; Ajami, K.; Yu, D.M.; Knott, H.; Seth, D. & McCaughan, 
G.W. (2006). Structure and function in dipeptidyl peptidase IV and related proteins. 
Adv Exp Med Biol 575:45-54. ISSN: 0065-2598 
Grisham, M.B.; Volkmer, C.; Tso, P. & Yamada, T. (1991). Metabolism of trinitrobenzene 
sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 
101:540-7. ISSN: 0016-5085 
Hanauer, S.B. (2006). Inflammatory bowel disease: epidemiology, pathogenesis, and 
therapeutic opportunities. Inflamm Bowel Dis 12 Suppl 1:S3-9. ISSN: 1536-4844 
Hanauer, S.B. & Hommes, D.W. (2010): Inflammatory bowel disease. Expert Rev Clin 
Immunol 6:499-500. ISSN: 1744-8409. 
Herrera, C.; Morimoto, C.; Blanco, J.; Mallol, J.; Arenzana, F.; Lluis, C. & Franco, R. (2001). 
Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem 276:19532-
9. ISSN: 0021-9258 
www.intechopen.com
 Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
86
Hildebrandt, M.; Reutter, W.; Arck, P.; Rose, M. & Klapp, B.F. (2000). A guardian angel: the 
involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, 
nutrition and immune defence. Clin Sci (Lond) 99:93-104. ISSN: 0143-5221 
Hildebrandt, M.; Rose, M.; Ruter, J.; Salama, A.; Monnikes, H. & Klapp, B.F. (2001). 
Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel 
disease. Scand J Gastroenterol 36:1067-72. ISSN: 0036-5521 
Howarth, G.S.; Xian, C.J. & Read, L.C. (2000). Predisposition to colonic dysplasia is 
unaffected by continuous administration of insulin-like growth factor-I for twenty 
weeks in a rat model of chronic inflammatory bowel disease. Growth Factors 
18(2):119-33. ISSN: 0897-7194 
Hyams, J.S.; Ferry, G.D.; Mandel, F.S.; Gryboski, J.D.; Kibort, P.M.; Kirschner, B.S.; Griffiths, 
A.M.; Katz, A.J.; Grand, R.J.; Boyle, J.T. et al. (1991). Development and validation of 
a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12:439-47. 
ISSN: 0277-2116 
Ikushima, H.; Munakata, Y.; Ishii, T.; Iwata, S.; Terashima, M.; Tanaka, H.; Schlossman, S.F. 
& Morimoto, C. (2000). Internalization of CD26 by mannose 6-phosphate/insulin-
like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci U S 
A 97:8439-44. ISSN: 0027-8424 
Ishii, T.; Ohnuma, K.; Murakami, A.; Takasawa, N.; Kobayashi, S.; Dang, N.H.; Schlossman, 
S.F. & Morimoto, C. (2001). CD26-mediated signaling for T cell activation occurs in 
lipid rafts through its association with CD45RO. Proc Natl Acad Sci U S A 98:12138-
43. ISSN: 0027-8424 
Iwanaga, T.; Hoshi, O.; Han, H. & Fujita, T. (1994). Morphological analysis of acute ulcerative 
colitis experimentally induced by dextran sulfate sodium in the guinea pig: some 
possible mechanisms of cecal ulceration. J Gastroenterol 29:430-8. ISSN: 0944-1174 
Kitajima, S.; Takuma, S. & Morimoto, M. (2000). Histological analysis of murine colitis 
induced by dextran sulfate sodium of different molecular weights. Exp Anim 49:9-
15. ISSN: 1341-1357 
Kreisel, W.; Heussner, R.; Volk, B.; Buchsel, R.; Reutter, W. & Gerok, W. (1982). Identification 
of the 110000 Mr glycoprotein isolated from rat liver plasma membrane as 
dipeptidylaminopeptidase IV. FEBS Lett 147:85-8. ISSN: 0014-5793 
Lambeir, A.M.; Durinx, C.; Proost, P.; Van Damme, J.; Scharpe, S. & De Meester, I. (2001). 
Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides 
involved in pancreatic insulin secretion. FEBS Lett 507:327-30. ISSN: 0014-5793 
Lambeir, A.M.; Durinx, C.; Scharpe, S. & De Meester, I. (2003). Dipeptidyl-peptidase IV from 
bench to bedside: an update on structural properties, functions, and clinical aspects 
of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209-94. ISSN: 1040-8363 
Mahler, M.; Bristol, I.J.; Leiter, E.H.; Workman, A.E.; Birkenmeier, E.H.; Elson, C.O. & 
Sundberg, J.P. (1998). Differential susceptibility of inbred mouse strains to dextran 
sulfate sodium-induced colitis. Am J Physiol 274:G544-51. ISSN: 0002-9513 
Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.M.; Pierres, M.; Nielsen, P.F.; Ribel, U.; 
Watanabe, T.; Drucker, D.J. & Wagtmann, N. (2000). Enhanced insulin secretion 
and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 
97:6874-9. ISSN: 0027-8424 
Matteucci, E. & Giampietro, O. (2009). Dipeptidyl Peptidase-4 (CD26): Knowing the 
Function before Inhibiting the Enzyme. Curr Med Chem 16:2943-51. ISSN: 0929-8673 
Mentlein, R. (1999). Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory 
peptides. Regul Pept 85:9-24. ISSN: 0167-0115 
www.intechopen.com
 Role of Dipeptidyl Peptidase IV/CD26 in Inflammatory Bowel Disease 
 
87 
Mentlein, R. (2004). Cell-surface peptidases. Int Rev Cytol 235:165-213. ISSN: 0074-7696 
Mizoguchi, A. & Mizoguchi, E. (2010). Animal models of IBD: linkage to human disease. 
Curr Opin Pharmacol 10:578-87. ISSN: 1471-4973 
Munoz, E.; Blazquez, M.V.; Madueno, J.A.; Rubio, G. & Pena, J. (1992). CD26 induces T-cell 
proliferation by tyrosine protein phosphorylation. Immunology 77:43-50. ISSN: 0019-2805 
Murthy, S.N.; Cooper, H.S.; Shim, H.; Shah, R.S.; Ibrahim, S.A. & Sedergran, D.J. (1993). 
Treatment of dextran sulfate sodium-induced murine colitis by intracolonic 
cyclosporin. Dig Dis Sci. 38(9):1722-34. ISSN: 0163-2116 
Nagatsu, I.; Nagatsu, T. & Yamamoto, T. (1968). Hydrolysis of amino acid beta-
naphthylamides by aminopeptidases in human parotid salva and human serum. 
Experientia 24:347-8. ISSN: 0014-4754 
Nemoto, E.; Sugawara, S.; Takada, H.; Shoji, S. & Horiuch, H. (1999). Increase of 
CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon 
stimulation with cytokines and bacterial components. Infect Immun 67:6225-33. 
ISSN: 0019-9567 
Ohkusa, T. (1985). (Production of experimental ulcerative colitis in hamsters by dextran 
sulfate sodium and changes in intestinal microflora). Nippon Shokakibyo Gakkai 
Zasshi (The Japanese journal of gastro-enterology) 82:1327-36. ISSN: 0446-6586 
Ohman, L. & Simren, M. (2010). Pathogenesis of IBS: role of inflammation, immunity and 
neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7:163-73. ISSN: 1759-5053 
Ohtsuka, Y. & Sanderson, I.R. (2003). Dextran sulfate sodium-induced inflammation is 
enhanced by intestinal epithelial cell chemokine expression in mice. Pediatr Res 
53:143-7. ISSN: 0031-3998 
Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y. &  Nakaya, R. (1990). A 
novel method in the induction of reliable experimental acute and chronic ulcerative 
colitis in mice. Gastroenterology 98:694-702. ISSN: 0016-5085 
Puschel, G.; Mentlein, R. & Heymann, E. (1982). Isolation and characterization of dipeptidyl 
peptidase IV from human placenta. Eur J Biochem 126:359-65. ISSN: 0014-2956 
Ravi, A.; Garg, P. & Sitaraman, S.V. (2007). Matrix metalloproteinases in inflammatory 
bowel disease: boon or a bane? Inflamm Bowel Dis 13:97-107. ISSN: 1536-4844  
Reinhold , D.; Bank, U.; Buhling, F.; Tager, M.; Born, I.; Faust, J.; Neubert, K. & Ansorge, S. 
(1997a). Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of 
transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes 
and thymocytes. Immunol Lett 58:29-35. ISSN: 0165-2478 
Reinhold, D.; Kahne, T.; Tager, M.; Lendeckel, U.; Buhling, F.; Bank, U.; Wrenger, S.; Faust, 
J.; Neubert, K.; & Ansorge, S. (1997b). The effect of anti-CD26 antibodies on DNA 
synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on 
enzymatic activity of DP IV/CD26. Adv Exp Med Biol 421:149-55. ISSN: 0065-2598 
Romijn, J.A.; Corssmit, E.P.; Havekes, L.M. & Pijl, H. (2008). Gut-brain axis. Curr Opin Clin 
Nutr Metab Care 11:518-21. ISSN: 1363-1950 
Rose, M.; Walter, O.B.; Fliege, H.; Hildebrandt, M.; Monnikes, H. & Klapp, B.F. (2003). DPP 
IV and mental depression in Crohn's disease. Adv Exp Med Biol 524:321-31. ISSN: 
0065-2598 
Scheiffele, F. & Fuss, I.J. (2002). Induction of TNBS colitis in mice. Curr Protoc Immunol 
Chapter 15:Unit 15 19. ISSN: 1934-368X 
www.intechopen.com
 Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
88
Schon, E.; Mansfeld, H.W.; Demuth, H.U.; Barth, A. & Ansorge, S. (1985). The dipeptidyl 
peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. 
Biomed Biochim Acta 44:K9-15. ISSN: 0232-766X 
Sedo, A. & Malik, R. (2001). Dipeptidyl peptidase IV-like molecules: homologous proteins or 
homologous activities? Biochim Biophys Acta 1550:107-16. ISSN: 0006-3002 
Shah, S.A. & Feller, E.R. (2009). Inflammatory bowel disease. Med Health R I 92:72. ISSN: 
1086-5462 
Strober, W.; Fuss, I.J.; Ehrhardt, R.O.; Neurath, M.; Boirivant, M. & Ludviksson, B.R. (1998) 
Mucosal immunoregulation and inflammatory bowel disease: new insights from 
murine models of inflammation. Scand J Immunol 48:453-8. ISSN: 0300-9475 
Thompson, M.A.; Ohnuma, K.; Abe, M.; Morimoto, C. & Dang, N.H. (2007). 
CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune 
disorders. Mini Rev Med Chem 7:253-73. ISSN: 1389-5575 
Truelove, S.C. & Witts, L.J. (1955). Cortisone in ulcerative colitis; final report on a 
therapeutic trial. Br Med J 2:1041-8. ISSN: 0007-1447 
Uhlig, H.H. & Powrie, F. (2009). Mouse models of intestinal inflammation as tools to 
understand the pathogenesis of inflammatory bowel disease. Eur J Immunol 
39:2021-6. ISSN: 1521-4141 
Vanderheyden, M.; Bartunek, J.; Goethals, M.; Verstreken, S.; Lambeir, A.M.; De Meester, I. 
& Scharpe, S. (2009). Dipeptidyl-peptidase IV and B-type natriuretic peptide. From 
bench to bedside. Clin Chem Lab Med 47:248-52. ISSN: 1434-6621 
Varljen, J., Sincic, B.M.; Baticic, L.; Varljen, N.; Detel, D. & Lekic, A. (2005). Clinical relevance of 
the serum dipeptidyl peptidase IV (DPP IV/CD26) activity in adult patients with 
Crohn's disease and ulcerative colitis. Croatica Chemica Acta 78:427-432. ISSN: 0011-1643 
Varljen, J.; Detel, D.; Lupis, T. & Peršić, M. (2004). Serum Dipeptidyl Peptidase IV (DPP 
IV/CD26) Activity in Children with Inflammatory Bowel Disease. Pediatric 
Gastroenterology 2004 - Reports from the 2nd World Congress of Pediatric 
Gastroenterology, Hepatology and Nutrition. Medimont S.r.l., 559-563. ISBN 88-
7587-106-X 
Willheim, M.; Ebner, C.; Baier, K.; Kern, W.; Schrattbauer, K.; Thien, R.; Kraft, D.; 
Breiteneder, H.; Reinisch, W. & Scheiner, O. (1997). Cell surface characterization of 
T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression 
with T(H1) subsets. J Allergy Clin Immunol 100:348-55. ISSN: 0091-6749 
Wirtz, S. & Neurath, M.F. (2007). Mouse models of inflammatory bowel disease. Adv Drug 
Deliv Rev 59:1073-83. ISSN: 0169-409X 
Yazbeck, R.; Howarth, G.S. & Abbott, C.A. (2009). Dipeptidyl peptidase inhibitors, an 
emerging drug class for inflammatory disease? Trends Pharmacol Sci 30:600-7. ISSN: 
1873-3735 
Yazbeck, R.; Howarth, G.S.; Geier, M.S.; Demuth, H.U. & Abbott, C.A. (2008). Inhibiting 
dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 
13:6850-8. ISSN: 1093-4715 
Yazbeck, R.; Sulda, M.L.; Howarth, G.S.; Bleich, A.; Raber, K.; von Horsten, S.; Holst, J.J. & 
Abbott, C.A. (2010). Dipeptidyl peptidase expression during experimental colitis in 
mice. Inflamm Bowel Dis 16:1340-51. ISSN: 1536-4844 
Yu, D.M.; Ajami, K.; Gall, M.G.; Park, J.; Lee, C.S.; Evans, K.A.; McLaughlin, E.A.; Pitman M.R.; 
Abbott, C.A.; McCaughan, G.W. & Gorrell, M.D. (2009). The in vivo expression of 
dipeptidyl peptidases 8 and 9. J Histochem Cytochem 57:1025-40. ISSN: 1551-5044 
www.intechopen.com
Inflammatory Bowel Disease - Advances in Pathogenesis and
Management
Edited by Dr. Sami Karoui
ISBN 978-953-307-891-5
Hard cover, 332 pages
Publisher InTech
Published online 27, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is dedicated to inflammatory bowel disease, and the authors discuss the advances in the
pathogenesis of inflammatory bowel disease, as well as several new parameters involved in the etiopathogeny
of Crohn's disease and ulcerative colitis, such as intestinal barrier dysfunction and the roles of TH 17 cells and
IL 17 in the immune response in inflammatory bowel disease. The book also focuses on several relevant
clinical points, such as pregnancy during inflammatory bowel disease and the health-related quality of life as
an end point of the different treatments of the diseases. Finally, advances in management of patients with
inflammatory bowel disease are discussed, especially in a complete review of the recent literature.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Dijana Detel, Lara Batičić Pučar, Ester Pernjak Pugel, Natalia Kučić, Sunčica Buljević, Brankica Mijandrušić
Sinčić, Mladen Peršić and Jadranka Varljen (2012). Role of Dipeptidyl Peptidase IV/CD26 in Inflammatory
Bowel Disease, Inflammatory Bowel Disease - Advances in Pathogenesis and Management, Dr. Sami Karoui
(Ed.), ISBN: 978-953-307-891-5, InTech, Available from: http://www.intechopen.com/books/inflammatory-
bowel-disease-advances-in-pathogenesis-and-management/role-of-dipeptidyl-peptidase-iv-cd26-in-
inflammatory-bowel-disease
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
